The Medication Assessment by Pharmacists (MAP) program at BC Cancer Surrey in Surrey, British Columbia, launched in 2019, integrates oncology pharmacists into a shared care model for patients with metastatic breast cancer receiving a CDK4/6 inhibitor. Here, CDK4 is linked to breast cancer.